Peapack Gladstone Financial Corp Sells 4,176 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Peapack Gladstone Financial Corp cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 27.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 11,267 shares of the company’s stock after selling 4,176 shares during the period. Peapack Gladstone Financial Corp’s holdings in Teva Pharmaceutical Industries were worth $203,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Sanctuary Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after buying an additional 664 shares during the period. TCW Group Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $1,286,000. Geode Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock valued at $157,571,000 after acquiring an additional 291,124 shares during the period. Finally, Barclays PLC grew its position in Teva Pharmaceutical Industries by 31.7% during the 3rd quarter. Barclays PLC now owns 427,595 shares of the company’s stock worth $7,705,000 after acquiring an additional 102,848 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $16.50 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company’s fifty day moving average price is $17.49 and its 200-day moving average price is $17.40. The stock has a market cap of $18.69 billion, a PE ratio of -19.41, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a 12 month low of $10.00 and a 12 month high of $19.31.

Insiders Place Their Bets

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Barclays increased their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.